NASDAQ: ALKS · Specialty & Generic Drug Manufacturers

Alkermes (ALKS) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Alkermes (ALKS) at $46.51 a share. The stock last closed at $46.53, which puts the model's fair value in line with the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Alkermes plc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$46.51midpoint of 2,000 simulations
Last close$46.53NASDAQ: ALKS
Gap to fair value0.0%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $44.12 to $46.51 (+5.4%). The companies the model compares it with now trade on higher multiples: most of the move.

What the model makes of itThe price of $46.53 is level with it: Fairly valued, on a medium evidence grade.

What's nextNext report on 24 Feb 2027. Options prices imply a move of about 14% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give ALKS?

The calibrated range for ALKS over 63 trading days is $39.62 to $55.08. It sits around the last close, and its width comes from the volatility that ALKS's own options imply (49% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $36.82 to $57.18. In 49% of the simulations the fair value came out above the price the model ran on.

$27.24$77.99
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $46.51. Dashed line: the last close, $46.53.

Faircurve Insights · 14 Nov 2026

Alkermes plc is a biopharmaceutical company. It researches, develops and commercialises pharmaceutical products for unmet medical needs in the United States, Ireland and internationally.

Faircurve's model put the fair value at $46.51 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $44.12, so the fair value moved +5.4%. The model gives the reason as: "The companies the model compares it with now trade on higher multiples: most of the move." The calibrated range over 63 trading days is $39.86 to $55.96. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It covers how complete the inputs are, the comparable companies and the spread of outcomes. It does not say whether the fair value is right.

The model's overall quality score is 41 out of 100. Balance sheet scores 3, with net debt to EBITDA at 5.26x. Profitability scores 7, with ROIC at 1.5%. Growth quality scores 55, with trailing revenue growth at -5.2% against a peer median of 16.7%. The model compares the company with Viatris Inc. (VTRS), Zoetis Inc. (ZTS) and ANI Pharmaceuticals, Inc. (ANIP).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does ALKS report earnings, and how has the stock reacted?

Alkermes's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 11.3% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ALKS's 30 day implied volatility works out to about 14.1% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ALKS's last 8 reports, ignoring direction, was 6.3%.

0%5%10%15%10.7%12.6%12 Feb '259.9%6.8%29 Jul '2513.5%5.8%28 Oct '2512.6%8.0%25 Feb '268.7%3.4%5 May '26no quote8.3%28 Jul '2610.7%2.4%28 Oct '2610.1%2.2%3 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in ALKS

5%10%15%20%25%3 Nov '26 report28 Oct '26 report28 Jul '26 report5 May '26 report25 Feb '26 report14% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 16% on 14 Nov 2025, reached 19% on 20 Feb 2026 and reads 14% on 16 Nov 2026. The marks are report dates.

How does ALKS score on business quality?

Alkermes's overall quality score is 41 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.71.5%ROIC
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).75
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.55-5.2%Revenue growth, trailing16.7%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.710.7%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.35.26xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.497.6 ptsEBITDA margin downside volatility, 5y40.7 pts

How does ALKS compare with similar companies?

The companies in specialty & generic drug manufacturers closest to Alkermes in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
AMRX Amneal Pharmaceuticals, Inc.$21.23$19.34-8.9%Low evidence grade
LNTH Lantheus Holdings, Inc.$101.72$100.47-1.2%Data under review
ELAN Elanco Animal Health Incorporated$26.41$25.34-4.1%Low evidence grade
VTRS Viatris Inc.$20.74$26.77+29.1%Undervalued
ZTS Zoetis Inc.$84.39$83.75-0.8%Fairly valued
SUPN Supernus, Inc.$28.83$29.86+3.6%Low evidence grade
ANIP ANI Pharmaceuticals, Inc.$70.89$78.16+10.3%Fairly valued
PAHC Phibro Animal Health Corporation$35.02$36.25+3.5%Low evidence grade

What the comparable companies' multiples alone would give for ALKS, the peer-implied price, is $42.16 a share on this run. The fair value weighs that against the company's own multiple.

All specialty & generic drug manufacturer stocks ranked by gap to fair value

Alkermes at a glance

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

Market value
$7.9B
Sector
Healthcare
Industry
Specialty & Generic Drug Manufacturers
Revenue expected, next twelve months
$1.9B
Consensus revenue growth, next fiscal year
+23.9%
Analysts with estimates
9
Beta to the US market
0.70
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ALKS was not among them.

How the fair value is worked out: the model prices Alkermes on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for ALKS was $44.12. As of 14 Nov 2026 it is $46.51, a change of +5.4%. The companies the model compares it with now trade on higher multiples: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Alkermes's valuation

Is Alkermes stock undervalued or overvalued?

On Faircurve's model, ALKS reads as Fairly valued as of 14 Nov 2026. The model's fair value is $46.51 a share against a last close of $46.53, a gap of 0.0%.

What is ALKS's fair value?

$46.51 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $36.82 to $57.18.

What price range does the model give ALKS?

$39.62 to $55.08 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Alkermes report earnings next?

The next report is scheduled for 24 Feb 2027. Companies can move their dates.

How much has ALKS moved on past earnings reports?

Across its last 8 reports the median two session move was 6.3%, ignoring direction. The largest was +12.6% around the report of 12 Feb 2025.

How confident is the model in this valuation?

The model's evidence grade for ALKS is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on ALKS

The model holds no idea open on ALKS today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ALKS with their outcomes. A free account is enough.

Keep reading